Literature DB >> 18688683

Resection versus laparoscopic radiofrequency thermal ablation of solitary colorectal liver metastasis.

Eren Berber1, Michael Tsinberg, Gurkan Tellioglu, Conrad H Simpfendorfer, Allan E Siperstein.   

Abstract

PURPOSE: There is scant data in the literature regarding radiofrequency thermal ablation (RFA) versus resection of colorectal liver metastases. The aim of this study is to compare the clinical profile and survival of patients with solitary colorectal liver metastasis undergoing resection versus laparoscopic RFA.
METHODS: Between 1996 and 2007, 158 patients underwent RFA (n = 68) and open liver resection (n = 90) of solitary liver metastasis from colorectal cancer. Patients were evaluated in a multidisciplinary fashion and allocated to a treatment type. Data were collected prospectively for the RFA patients and retrospectively for the resection patients.
RESULTS: Although the groups were matched for age, gender, chemotherapy exposure and tumor size, RFA patients tended to have a higher ASA score and presence of extra-hepatic disease (EHD) at the time of treatment. The main indication for referral to RFA included technical reasons (n = 25), patient comorbidities (n = 24), extra-hepatic disease (n = 10) and patient decision (n = 9). There were no peri-operative mortalities in either group. The complication rate was 2.9% (n = 2) for RFA and 31.1% (n = 28) for resection. The overall Kaplan-Meier median actuarial survival from the date of surgery was 24 months for RFA patients with EHD, 34 months for RFA patients without EHD and 57 months for resection patients (p < 0.0001). The 5-year actual survival was 30% for RFA patients and 40% for resection patients (p = 0.35).
CONCLUSIONS: This study shows that, although patients in both groups had a solitary liver metastasis, other factors including medical comorbidities, technically challenging tumor locations and extra-hepatic disease were different, prompting selection of therapy. With a simultaneous ablation program, higher risk patients have been channeled to RFA, leaving a highly selected group of patients for resection with a very favorable survival. RFA still achieved long-term survival in patients who were otherwise not candidates for resection.

Entities:  

Mesh:

Year:  2008        PMID: 18688683     DOI: 10.1007/s11605-008-0622-8

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  19 in total

Review 1.  Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors.

Authors:  Stefaan Mulier; Yicheng Ni; Jacques Jamart; Theo Ruers; Guy Marchal; Luc Michel
Journal:  Ann Surg       Date:  2005-08       Impact factor: 12.969

2.  Long-term survival after radiofrequency ablation of complex unresectable liver tumors.

Authors:  Farin F Amersi; Ana McElrath-Garza; Aziz Ahmad; Theresa Zogakis; David P Allegra; Robert Krasne; Anton J Bilchik
Journal:  Arch Surg       Date:  2006-06

3.  Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis.

Authors:  S A Curley; F Izzo; L M Ellis; J Nicolas Vauthey; P Vallone
Journal:  Ann Surg       Date:  2000-09       Impact factor: 12.969

4.  Long-term outcome of radiofrequency ablation for unresectable liver metastases from colorectal cancer: evaluation of prognostic factors and effectiveness in first- and second-line management.

Authors:  Junji Machi; Andrew J Oishi; Kenneth Sumida; Kazuhiro Sakamoto; Nancy L Furumoto; Robert H Oishi; Jelle W Kylstra
Journal:  Cancer J       Date:  2006 Jul-Aug       Impact factor: 3.360

5.  Radiofrequency ablation of 231 unresectable hepatic tumors: indications, limitations, and complications.

Authors:  T F Wood; D M Rose; M Chung; D P Allegra; L J Foshag; A J Bilchik
Journal:  Ann Surg Oncol       Date:  2000-09       Impact factor: 5.344

6.  Local recurrence after laparoscopic radiofrequency thermal ablation of hepatic tumors.

Authors:  A Siperstein; A Garland; K Engle; S Rogers; E Berber; A Foroutani; A String; T Ryan; P Ituarte
Journal:  Ann Surg Oncol       Date:  2000-03       Impact factor: 5.344

7.  Comparison of resection and radiofrequency ablation for treatment of solitary colorectal liver metastases.

Authors:  A Oshowo; A Gillams; E Harrison; W R Lees; I Taylor
Journal:  Br J Surg       Date:  2003-10       Impact factor: 6.939

8.  Predictors of survival after laparoscopic radiofrequency thermal ablation of hepatocellular cancer: a prospective study.

Authors:  E Berber; S Rogers; A Siperstein
Journal:  Surg Endosc       Date:  2005-03-11       Impact factor: 4.584

9.  Laparoscopic radiofrequency ablation of liver tumors combined with colorectal procedures.

Authors:  Eren Berber; Anthony Senagore; Feza Remzi; Stanley Rogers; Nora Herceg; Karen Casto; Allan Siperstein
Journal:  Surg Laparosc Endosc Percutan Tech       Date:  2004-08       Impact factor: 1.719

10.  Radiofrequency ablation versus resection for resectable colorectal liver metastases: time for a randomized trial?

Authors:  Stefaan Mulier; Yicheng Ni; Jacques Jamart; Luc Michel; Guy Marchal; Theo Ruers
Journal:  Ann Surg Oncol       Date:  2007-09-29       Impact factor: 5.344

View more
  32 in total

1.  Computed tomography (CT)-guided versus laparoscopic radiofrequency ablation: a single-institution comparison of morbidity rates and hospital costs.

Authors:  Maria A Cassera; Kevin W Potter; Michael B Ujiki; Lee L Swanström; Paul D Hansen
Journal:  Surg Endosc       Date:  2010-09-17       Impact factor: 4.584

Review 2.  Radiofrequency ablation versus resection for liver tumours: an evidence-based approach to retrospective comparative studies.

Authors:  Gianpiero Gravante; John Overton; Roberto Sorge; Neil Bhardwaj; Matthew S Metcalfe; David M Lloyd; Ashley R Dennison
Journal:  J Gastrointest Surg       Date:  2011-02       Impact factor: 3.452

3.  General principles of hepatectomy in colorectal liver metastases.

Authors:  I Maroulis; D D Karavias; D Karavias
Journal:  Tech Coloproctol       Date:  2011-10       Impact factor: 3.781

Review 4.  Chinese guidelines for the diagnosis and comprehensive treatment of hepatic metastasis of colorectal cancer.

Authors:  Jianmin Xu; Xinyu Qin; Jianping Wang; Suzhan Zhang; Yunshi Zhong; Li Ren; Ye Wei; Shaochong Zeng; Deseng Wan; Shu Zheng
Journal:  J Cancer Res Clin Oncol       Date:  2011-07-28       Impact factor: 4.553

Review 5.  Pancreatic neuroendocrine tumors.

Authors:  Shailesh V Shrikhande; Bhawna Sirohi; Mahesh Goel; Savio G Barreto
Journal:  Indian J Gastroenterol       Date:  2012-10-03

6.  [Metastases of colorectal carcinoma].

Authors:  S Clasen; H Rempp; P L Pereira
Journal:  Radiologe       Date:  2008-11       Impact factor: 0.635

7.  Incidence and treatment of local site recurrences following RFA of colorectal liver metastases.

Authors:  Karin Nielsen; Aukje A J M van Tilborg; Martijn R Meijerink; Matessa O Macintosh; Babs M Zonderhuis; Elly S M de Lange; Emile F I Comans; Sybren Meijer; M Petrousjka van den Tol
Journal:  World J Surg       Date:  2013-06       Impact factor: 3.352

8.  Long-term outcomes following hepatic resection and radiofrequency ablation of colorectal liver metastases.

Authors:  Andrew McKay; Katherine Fradette; Jeremy Lipschitz
Journal:  HPB Surg       Date:  2010-02-01

9.  A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment.

Authors:  Nikol Snoeren; Emile E Voest; Andre M Bergman; Otilia Dalesio; Henk M Verheul; Rob A E M Tollenaar; Joost R M van der Sijp; Sander B Schouten; Inne H M Borel Rinkes; R van Hillegersberg
Journal:  BMC Cancer       Date:  2010-10-11       Impact factor: 4.430

10.  A comparison of perioperative outcomes in elderly patients with malignant liver tumors undergoing laparoscopic liver resection versus radiofrequency ablation.

Authors:  Pinar Yazici; Muhammet Akyuz; Hakan Yigitbas; Cem Dural; Alexis Okoh; Nail Aydin; Eren Berber
Journal:  Surg Endosc       Date:  2016-07-21       Impact factor: 4.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.